Pfizer Documents Court Release: "FDA Was Hiding Vaccine Data"

Introduction

In January 2022, U.S. District Judge Mark Pittman ordered the Food and Drug Administration to produce Pfizer BioNTech COVID-19 vaccine documents at a rate of 55,000 pages per month — a pace that would complete the disclosure in approximately eight months. The FDA had proposed releasing 500 pages per month, which would have taken approximately 75 years to complete. The court agreed that the FDA''s proposed pace was unreasonable and ordered the accelerated schedule.

The release became the source of one of the most durable post-pandemic social-media narratives: that the FDA had wanted to "hide" proof of mass vaccine harm for 75 years, and that the released documents confirmed the vaccine was far more dangerous than the public had been told. The claim spread widely across platforms including Twitter (now X), Telegram, and Substack, accompanied by images of adverse-event tables from the documents.

This page examines what the documents actually contain, why the 75-year figure emerged, what the adverse-event tables represent, and why the "hidden harm" framing overclaims.

Background: PHMPT v. FDA

The litigation was brought by the Public Health and Medical Professionals for Transparency (PHMPT), a group that submitted a FOIA request for Pfizer''s vaccine approval documents. The FDA''s initial response — the 500-pages-per-month proposal — prompted the lawsuit.

Judge Pittman ruled in January 2022 that the FDA had to produce the documents at the accelerated 55,000-page monthly rate. The FDA complied; subsequent releases produced hundreds of thousands of pages of clinical-trial and post-market surveillance data. By mid-2022 the bulk of the documents had been publicly released and were available on the FDA website. The PHMPT also posted them on a publicly accessible site.

The documents included:

• Clinical-trial data submitted to the FDA as part of the Emergency Use Authorization and subsequent Biologics License Application
• Post-market adverse-event reports compiled from the Vaccine Adverse Event Reporting System (VAERS) and other passive surveillance inputs
• Manufacturing documentation
• FDA internal review memos and correspondence

The "75 Years" Figure

The 75-year figure comes from the FDA''s proposed FOIA release timeline. Under standard FOIA processing, the FDA receives thousands of requests and processes them in order. The agency argued that producing 55,000 pages per month would require diverting significant staff resources from other priority work. The 75-year estimate was a projection of how long it would take at the slower rate.

The framing that the FDA "wanted to keep it hidden for 75 years" represents a misreading of bureaucratic resource planning as deliberate concealment. FOIA backlogs at large agencies are routine; the FDA processes medical and pharmaceutical records across thousands of drug programs. The 75-year figure reflected queue depth, not a decision to conceal specific documents from specific people.

Critically, the FDA had already approved and licensed the Pfizer vaccine by the time the litigation began. The clinical-trial data had already been reviewed by FDA scientists in producing that approval. The data existed; the FOIA request was asking for the documents underlying a completed review.

What the Adverse-Event Tables Actually Are

The document that circulated most widely showed a table of adverse events compiled under the heading "Cumulative Analysis of Post-Authorization Adverse Event Reports" — commonly called the "5.3.6" document by its section number in Pfizer''s submission. The table lists thousands of adverse-event terms.

Several things are critical to understanding what this table represents:

Post-authorization passive surveillance, not clinical-trial data. The table is not a list of confirmed vaccine injuries. It is a compilation of adverse events reported to Pfizer through post-market surveillance systems in the first approximately three months after EUA authorization (through February 28, 2021). This type of report is legally required for all authorized medications; pharmaceutical companies must submit cumulative adverse-event summaries to regulators as part of ongoing pharmacovigilance.

Passive surveillance reports are not causation determinations. VAERS and equivalent systems accept reports of any adverse event that occurs after vaccination, regardless of whether a causal relationship has been established. A person who was vaccinated and subsequently experienced any medical event — broken bone, stroke, cancer recurrence — is encouraged to report. This systematic over-inclusion is a feature, not a bug: it ensures rare signals are captured. But it also means the raw count of reported events is not a count of vaccine-caused injuries.

The numbers were not surprising to pharmacovigilance scientists. Given the hundreds of millions of doses administered in the first months, adverse-event counts in the tens of thousands are expected under passive surveillance. Regulators compare reported rates to background rates for each condition in the relevant population. The FDA and international regulators (EMA, MHRA, Health Canada) all reviewed the same data sets and found the known adverse-event profile — including rare myocarditis (primarily in young males after the second dose) — consistent with the benefit-risk calculation underlying authorization.

Some adverse events are real and documented. The claim that the documents reveal "nothing alarming" is also an overclaim. Myocarditis and pericarditis were identified as rare adverse events and are now prominently listed in Pfizer''s label. The clinical-trial exclusion of certain populations (pregnancy, immunocompromised) was a real limitation, later addressed by specific supplementary studies. The FDA''s own reporting acknowledges these signals.

Follow-on FOIA: ICAN and the V-safe Data

A parallel transparency case sharpened public skepticism about CDC and FDA pharmacovigilance practices. In 2021 the Informed Consent Action Network sued the CDC for release of V-safe vaccine safety monitoring data, a smartphone check-in system that registrants used in the months after vaccination. After litigation, the CDC produced batches of V-safe records through late 2022 and 2023. The data showed that roughly 7.7 percent of V-safe registrants who completed a check-in reported a health impact within the first week after vaccination — meaning they sought medical care, could not perform normal activities, or missed school or work.

That figure was widely circulated as further proof of hidden mass harm. The CDC has consistently responded that V-safe is a voluntary post-vaccination check-in tool, not a vaccine-injury reporting system: a self-reported "health impact" is not a determination of vaccine causation. The same passive-surveillance caveats that apply to VAERS apply to V-safe — systematic over-inclusion to ensure rare signals surface, not a count of confirmed injuries. The episode is a faithful rerun of the Pfizer-documents pattern: a real transparency failure on the agency side, real underlying data, and a consistent overreading of routine pharmacovigilance as concealed harm.

Why the Verdict Is "Partially True"

The documents are real, publicly available, and contain information about adverse events. The court order was necessary and appropriate; the FDA''s proposed 75-year timeline was genuinely unreasonable for a matter of significant public health interest.

The "hidden harm" framing, however, overclaims in several directions:

• The adverse-event tables do not represent concealed data; they are standard pharmacovigilance reports submitted as part of required post-market surveillance
• The 75-year framing misrepresents FOIA processing backlogs as intentional concealment
• The specific figures in the tables do not indicate that vaccine harms were systematically underreported; the data align with what regulators and researchers had already published
• The documents have been reviewed extensively by academic researchers, journalists, and independent scientists since their release; no significant pattern of concealed serious harm has emerged from that review

Some legitimate concerns are embedded in the story: the initial FOIA pace was inappropriate; routine communication of the adverse-event monitoring process to the public was insufficient; and some specific adverse-event signals (myocarditis in young males) were real and warranted the label changes they eventually received.

What Would Change Our Verdict

• Peer-reviewed analysis of the released documents identifying a pattern of adverse events that regulators knew about and withheld from public communication
• Documentary evidence that FDA scientists reviewed data showing mass harm and suppressed findings
• Independent replication of the adverse-event rates from the documents at levels inconsistent with what was publicly reported

Verdict

Partially true. The court order, the documents, and the adverse-event tables are all real. The FDA''s proposed 75-year release timeline was appropriately challenged and overturned. The "FDA was hiding evidence of mass harm" framing is an overclaim: the adverse-event tables are routine pharmacovigilance data, their content aligns with what was already publicly known, and extensive post-release review has not revealed a pattern of suppressed serious harm. Distinguishing "FOIA backlog" from "deliberate concealment" is essential to accurately reading this story.